Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
1. Johnson & Johnson reports Q4 earnings Wednesday with $2 EPS expectations. 2. FDA approves Spravato for major depressive disorder, boosting JNJ's psychiatric portfolio. 3. Short-term indicators bullish; long-term trends show potential weakness. 4. Analysts expect 13% upside with a price target of $167.71.